Evaluation of the clinical efficacy of anagliptin in type 2 diabetic patients with diabetic nephropathy.
Not Applicable
- Conditions
- Type 2 diabetes with diabetic nephropathy
- Registration Number
- JPRN-UMIN000012802
- Lead Sponsor
- Kanazawa Medical University Diabetology and Endocrinology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patient have been treated with DPP-4 inhibitors within 12 weeks before the study. 2.Patient have been treated with insulins, rapid acting insulin secretagogues, or a high dose of SU (glimepiride > 2mg/day, gliclazide > 40mg/day, glibenclamide > 1.25mg/day). 3.Patient who have a history of allergy to anagliptin. 4.Patients who have severe ketosis, diabetic coma, diabetic pre-coma, or type 1 diabetes 5.Patients who have severe infection,
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method